Edwards Lifesciences (EW) Accounts Payables (2016 - 2025)
Edwards Lifesciences (EW) has 17 years of Accounts Payables data on record, last reported at $227.5 million in Q4 2025.
- For Q4 2025, Accounts Payables rose 15.25% year-over-year to $227.5 million; the TTM value through Dec 2025 reached $227.5 million, up 15.25%, while the annual FY2025 figure was $227.5 million, 15.25% up from the prior year.
- Accounts Payables reached $227.5 million in Q4 2025 per EW's latest filing, up from $165.0 million in the prior quarter.
- Across five years, Accounts Payables topped out at $861.1 million in Q2 2021 and bottomed at $139.5 million in Q3 2021.
- Average Accounts Payables over 5 years is $248.9 million, with a median of $186.6 million recorded in 2023.
- Peak YoY movement for Accounts Payables: crashed 83.03% in 2021, then rose 23.05% in 2023.
- A 5-year view of Accounts Payables shows it stood at $204.5 million in 2021, then fell by 1.27% to $201.9 million in 2022, then dropped by 7.58% to $186.6 million in 2023, then increased by 5.79% to $197.4 million in 2024, then grew by 15.25% to $227.5 million in 2025.
- Per Business Quant database, its latest 3 readings for Accounts Payables were $227.5 million in Q4 2025, $165.0 million in Q3 2025, and $162.1 million in Q2 2025.